Compare Stocks
Compare up to four stocks to (ALNY) by adding the symbol or company name.
ALNY
| Compare up to three stocks to ALNY by adding the symbol or company name. | Add Stock | Add Stock | Add Stock |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Market Value | Market Value 19.15B | Market Value -- | Market Value -- | Market Value -- |
| Enterprise Value | EV 17.96B | EV -- | EV -- | EV -- |
| Price to Earnings | Price to Earnings -- | Price to Earnings -- | Price to Earnings -- | Price to Earnings -- |
| Diluted Earnings Per Share | Diluted EPS TTM -2.64 | Diluted EPS TTM -- | Diluted EPS TTM -- | Diluted EPS TTM -- |
| Forward Dividend & Yield | Fwd Div Yld -- | Fwd Div Yld -- | Fwd Div Yld -- | Fwd Div Yld -- |
| Sector | Sector Healthcare | Sector -- | Sector -- | Sector -- |
| Industry | Industry Biotechnology | Industry -- | Industry -- | Industry -- |
| CEO | CEO Dr. Yvonne L. Greenstreet M.B.A., MBChB | CEO -- | CEO -- | CEO -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| 1 Week | 1 Week 0.11% | 1 Week -- | 1 Week -- | 1 Week -- |
| 3 Months | 3 Months -11.50% | 3 Months -- | 3 Months -- | 3 Months -- |
| YTD | YTD -21.39% | YTD -- | YTD -- | YTD -- |
| 1 Year | 1 Year -27.60% | 1 Year -- | 1 Year -- | 1 Year -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Revenue | Revenue 2.00B | Revenue -- | Revenue -- | Revenue -- |
| Operating Expenses | Operating Expenses 1.86B | Operating Expenses -- | Operating Expenses -- | Operating Expenses -- |
| Operating Income | Operating Income -175.80M | Operating Income -- | Operating Income -- | Operating Income -- |
| Revenue Growth YoY | Rev Gr 1Y 54.82% | Rev Gr 1Y -- | Rev Gr 1Y -- | Rev Gr 1Y -- |
| Gross Profit | Gross Profit 1.68B | Gross Profit -- | Gross Profit -- | Gross Profit -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Inventory | Inventory 93.99M | Inventory -- | Inventory -- | Inventory -- |
| Account Receivables Turnover | A/R Turnover 7.41 | A/R Turnover -- | A/R Turnover -- | A/R Turnover -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Cash Flow from Operations | CF from Ops 189.12M | CF from Ops -- | CF from Ops -- | CF from Ops -- |
| Capital Expenditures | CapEx -61.29M | CapEx -- | CapEx -- | CapEx -- |
| Cash from Investing Activities | CFI -327.75M | CFI -- | CFI -- | CFI -- |
| Free Cash Flow | Free Cash Flow 127.82M | Free Cash Flow -- | Free Cash Flow -- | Free Cash Flow -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Price to Earnings Per Share | P/E -- | P/E -- | P/E -- | P/E -- |
| Forward Price to Earnings Per Share | Fwd P/E -- | Fwd P/E -- | Fwd P/E -- | Fwd P/E -- |
| Price to Free Cash Flow Per Share | P/FCF 147.63 | P/FCF -- | P/FCF -- | P/FCF -- |
| Price to Book Value Per Share | P/BV -- | P/BV -- | P/BV -- | P/BV -- |
| Price to Sales Ratio | P/S 9.42 | P/S -- | P/S -- | P/S -- |
| EV/EBITDA | EV/EBITDA -180.52 | EV/EBITDA -- | EV/EBITDA -- | EV/EBITDA -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Operating Margin | Oper. Margin -8.78% | Oper. Margin -- | Oper. Margin -- | Oper. Margin -- |
| Gross Margin | Gross Margin 83.95% | Gross Margin -- | Gross Margin -- | Gross Margin -- |
| Profit Margin | Profit Margin -16.58% | Profit Margin -- | Profit Margin -- | Profit Margin -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Basic Earnings Per Share | EPS -2.64 | EPS -- | EPS -- | EPS -- |
| EPS 1Yr Growth | EPS 1Yr Growth 0.00% | EPS 1Yr Growth -- | EPS 1Yr Growth -- | EPS 1Yr Growth -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Return on Assets | Return on Assets -9.20% | Return on Assets -- | Return on Assets -- | Return on Assets -- |
| Return on Capital | Return on Capital -81.77% | Return on Capital -- | Return on Capital -- | Return on Capital -- |
| As of May 11, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | -- | -- | -- |
|---|---|---|---|---|
| Institutional Ownership % | Inst. Own. % 94.44% | Inst. Own. % -- | Inst. Own. % -- | Inst. Own. % -- |